Primary Immune Deficiency (PID) - Pipeline Review, H2 2015

Date: November 30, 2015
Pages: 72
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P147B23232CEN
Leaflet:

Download PDF Leaflet

Primary Immune Deficiency (PID) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Primary Immune Deficiency (PID) - Pipeline Review, H2 2015’, provides an overview of the Primary Immune Deficiency (PID)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Primary Immune Deficiency (PID), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Immune Deficiency (PID) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Primary Immune Deficiency (PID) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Primary Immune Deficiency (PID) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Primary Immune Deficiency (PID) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Primary Immune Deficiency (PID)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Primary Immune Deficiency (PID) Overview
Therapeutics Development
Pipeline Products for Primary Immune Deficiency (PID) - Overview
Pipeline Products for Primary Immune Deficiency (PID) - Comparative Analysis
Primary Immune Deficiency (PID) - Therapeutics under Development by Companies
Primary Immune Deficiency (PID) - Therapeutics under Investigation by Universities/Institutes
Primary Immune Deficiency (PID) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Primary Immune Deficiency (PID) - Products under Development by Companies
Primary Immune Deficiency (PID) - Products under Investigation by Universities/Institutes
Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
ADMA Biologics, Inc.
Baxalta Incorporated
Bellicum Pharmaceuticals, Inc.
Genethon
GlaxoSmithKline Plc
Green Cross Corporation
Octapharma AG
ProMetic Life Sciences Inc.
Sangamo BioSciences, Inc.
Sanofi
Primary Immune Deficiency (PID) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(immune globulin (human) + hyaluronidase (recombinant)) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BPX-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2696273 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NewNorm - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OT-81 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plerixafor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RI-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Primary Immune Deficiency (PID) - Recent Pipeline Updates
Primary Immune Deficiency (PID) - Dormant Projects
Primary Immune Deficiency (PID) - Product Development Milestones
Featured News & Press Releases
Nov 03, 2015: ADMA Biologics Announces Data to be Presented at the International Primary Immunodeficiencies Congress in Budapest, Hungary
Oct 26, 2015: Prometic’s IVIG IND Cleared By FDA
Sep 30, 2015: ADMA Biologics Receives Milestone Payment From Biotest for RI-002 BLA Submission to FDA
Sep 21, 2015: FDA Accepts ADMA Biologics License Application for RI-002
Aug 31, 2015: ADMA Biologics Receives Patent Issuance Pertaining to the Treatment of Immunodeficiency
Aug 03, 2015: Baxalta Announces Expanded CMS Coverage for Medicare PI Patients to Receive At-Home Treatment with HYQVIA
Jun 30, 2015: ADMA Biologics Receives Notice of Allowance for U.S. Patent Pertaining to Its Lead Product Candidate RI-002
Apr 27, 2015: GlaxoSmithKline Close To File For Marketing Approval For ADA-SCID Therapy In EU
Feb 23, 2015: ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference
Feb 17, 2015: ADMA Biologics Announces Data to be Presented at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Primary Immune Deficiency (PID), H2 2015
Number of Products under Development for Primary Immune Deficiency (PID) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics, Inc., H2 2015
Primary Immune Deficiency (PID) - Pipeline by Baxalta Incorporated, H2 2015
Primary Immune Deficiency (PID) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Primary Immune Deficiency (PID) - Pipeline by Genethon, H2 2015
Primary Immune Deficiency (PID) - Pipeline by GlaxoSmithKline Plc, H2 2015
Primary Immune Deficiency (PID) - Pipeline by Green Cross Corporation, H2 2015
Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H2 2015
Primary Immune Deficiency (PID) - Pipeline by ProMetic Life Sciences Inc., H2 2015
Primary Immune Deficiency (PID) - Pipeline by Sangamo BioSciences, Inc., H2 2015
Primary Immune Deficiency (PID) - Pipeline by Sanofi, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Primary Immune Deficiency (PID) Therapeutics - Recent Pipeline Updates, H2 2015
Primary Immune Deficiency (PID) - Dormant Projects, H2 2015

LIST OF FIGURES

Number of Products under Development for Primary Immune Deficiency (PID), H2 2015
Number of Products under Development for Primary Immune Deficiency (PID) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015
Skip to top


Ask Your Question

Primary Immune Deficiency (PID) - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: